Literature DB >> 2917279

The Bereitschaftspotential is abnormal in Parkinson's disease.

J P Dick1, J C Rothwell, B L Day, R Cantello, O Buruma, M Gioux, R Benecke, A Berardelli, P D Thompson, C D Marsden.   

Abstract

The average Bereitschaftspotential (BP) preceding a rapid, self-paced voluntary extension movement of the index finger was recorded from 6 scalp locations in 14 patients with Parkinson's disease who had been withdrawn from their normal drug therapy for at least 12 h before testing. The amplitude of the potential was measured at the peak negativity (N1) and 650 ms prior to this (NS1), and compared with that recorded in a group of 12 age-matched control subjects. The N1 amplitude was the same as in the normals, but the NS1 component was smaller in the patients, especially in midline leads. As a result, the rise in the BP between the peak NS1 and N1 component (termed NS2) was larger in the patient group. The NS1 component of the BP is thought to reflect preparatory activity in the supplementary motor area (SMA) of cortex. Since the basal ganglia provide a major source of afferent input to SMA, the reduction in NS1 in the patients probably results from inadequate basal ganglia activation of SMA. The larger NS2 component may reflect extra activity in other brain areas to compensate for the reduced SMA activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917279     DOI: 10.1093/brain/112.1.233

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  39 in total

1.  Role of primate basal ganglia and frontal cortex in the internal generation of movements. III. Neuronal activity in the supplementary motor area.

Authors:  R Romo; W Schultz
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 2.  Motor control abnormalities in Parkinson's disease.

Authors:  Pietro Mazzoni; Britne Shabbott; Juan Camilo Cortés
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  Motivational engagement in Parkinson's disease: Preparation for motivated action.

Authors:  J B Renfroe; M M Bradley; M S Okun; D Bowers
Journal:  Int J Psychophysiol       Date:  2015-12-01       Impact factor: 2.997

4.  Contributions of the dopaminergic system to voluntary and automatic orienting of visuospatial attention.

Authors:  S Yamaguchi; S Kobayashi
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

5.  Rate-dependent impairments in repetitive finger movements in patients with Parkinson's disease are not due to peripheral fatigue.

Authors:  Elizabeth L Stegemöller; David P Allen; Tanya Simuni; Colum D MacKinnon
Journal:  Neurosci Lett       Date:  2010-06-25       Impact factor: 3.046

Review 6.  Neurophysiological markers of network dysfunction in neurodegenerative diseases.

Authors:  Roisin McMackin; Peter Bede; Niall Pender; Orla Hardiman; Bahman Nasseroleslami
Journal:  Neuroimage Clin       Date:  2019-02-02       Impact factor: 4.881

7.  Effects of Parkinson disease and antiparkinson medication on central adaptations to repetitive grasping.

Authors:  Michael J Falvo; John W Rohrbaugh; Thomas Alexander; Gammon M Earhart
Journal:  Life Sci       Date:  2018-03-09       Impact factor: 5.037

8.  Abnormal movement related potentials in patients with lesions of basal ganglia and anterior thalamus.

Authors:  A Fève; N Bathien; P Rondot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

9.  Three-dimensional localization of SMA activity preceding voluntary movement. A study of electric and magnetic fields in a patient with infarction of the right supplementary motor area.

Authors:  W Lang; D Cheyne; R Kristeva; R Beisteiner; G Lindinger; L Deecke
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

10.  Spatiotemporal study of Bereitschaftspotential and event-related desynchronization during voluntary movement in Parkinson's disease.

Authors:  L Defebvre; J L Bourriez; K Dujardin; P Derambure; A Destée; J D Guieu
Journal:  Brain Topogr       Date:  1994       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.